Tag - NLSP

Markets

Maxim ups NLS Pharma to buy on funding from BVF Partners

Maxim Group upgraded NLS Pharmaceuticals (NASDAQ:NLSP) to “buy” from “hold” with a new $4 price target. The stock closed at 88 cents on Dec. 7 when NLS announced a purchase agreement with BVF Partners, a leading...

December 8, 2022

Markets

Maxim starts NLS Pharmaceutics at buy; PT $8

Maxim Group launched coverage of NLS Pharmaceutics AG (NASDAQ:NLSP) with a “buy” rating and $8 price target. The stock closed at $2.83 on March 2. NLS is developing Quilience for narcolepsy and Nolazol for ADHD; both...

March 3, 2021

Tag - NLSP

Maxim ups NLS Pharma to buy on funding from BVF Partners

Maxim starts NLS Pharmaceutics at buy; PT $8

General

More